Canadian Drugstore Reveals New Way to Prevent Cervical Cancer

Canadian drugstore online believes that cervical cancer is one of the leading causes why women take Canadian prescription drugs , and if not alleviated in its early stage could to death.  As such, to prevent its precursors is a great feat in science.  That is, with the introduction of a human papillomavirus (HPV) vaccine in Canada pharmacies , a significant decrease of high-grade cervical irregularities which are precursors of cervical cancer was concluded by a new research study.

The study focused on Australian women in particular.  The researchers evaluated developments in high-grade cervical malfunctions, or HGAs, among ladies in Victoria, Australia before and after immunization of a national HPV vaccine program for all females from 12 to 26 years of age.

"Our finding that the decrease in HGA incidence occurred in the youngest vaccination cohort before it occurred in the older, catch-up cohorts (who were more likely to have been previously sexually experienced) reinforces the appropriateness of the targeting of prophylactic HPV vaccines to preadolescent girls," Dr. Julia Brotherton, of Victorian Cytology Service Registries, together with her colleagues recorded in the report published in the June 2011 issue of The Lancet.

"This is the first report of a decrease in incidence of HGAs within three years after the implementation of a population-wide HPV vaccination program," highlighted by the study authors.

In their statement, Dr. Mona Saraiya and Susan Hariri, of the U.S. Centers for Disease Control and Prevention, wrote: "The not-so-cautious optimist in us wants to hail this early finding as true evidence of vaccine effect. However, individual-level vaccine status was not considered -- as it perhaps should have been in view of the availability of such data in Victoria, [Australia]."

Also, "as stated by Brotherton and colleagues, linkage between vaccination and screening registers is needed to confirm these findings independently of possible bias by screening policy or practice changes. Indeed, more rigorous epidemiological studies are needed -- many are underway -- to increase our understanding of HPV vaccine effectiveness against cervical disease," Saraiya and Hariri further added.

"A demonstrable reduction of the burden of cervical cancer -- the main goal of HPV vaccines -- will take several decades," concluded by the editorialists.

Dr. Elizabeth A. Poynor, a gynecologic oncologist and pelvic surgeon at Lenox Hill Hospital in New York City, stated: "This study is the first report on a large scale HPV vaccination program, outside the setting of a clinical trial.”

"It demonstrates the important finding that an HPV vaccination program can lead to a lower incidence of significant HPV-related disease in young women. Because the study is not strong enough to demonstrate a "cause and effect," it therefore should be approached with cautious optimism," she said.